

J. Brighton  
6/5/01 A

S/N Unknown

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Clifford P. Stanners et al.

Examiner: Unknown

Serial No.: Unknown

Group Art Unit: Unknown

Filed: Herewith

Docket: 186.009US1

Title: CEA/NCA-BASED DIFFERENTIATION CANCER THERAPY

**PRELIMINARY AMENDMENT**

**BOX PATENT APPLICATION**

Commissioner for Patents

Washington, D.C. 20231

Dear Sir:

Prior to examination of the above-identified patent application, please amend as follows.

**IN THE SPECIFICATION**

On the first page, after the title, please insert:

--Cross-Reference to related Applications

This application is a continuation of International Patent Application No.

A | PCT/CA99/00119, filed on February 11, 1999, which in turn is an international filing of Canadian Patent Application No. 2,224,129 filed on February 12, 1998, all of which are incorporated herein by reference.--

**IN THE CLAIMS**

Please amend as follows:

Please cancel claims 1-11.

*Sub Cl 1*  
12. (NEW) An Anti-CEA/NCA antibody which specifically interacts with a subdomain of CEA/NCA, wherein said subdomain is selected from the group consisting of sequences G<sub>30</sub>YSWYK, N<sub>42</sub>RQII, and Q<sub>80</sub>ND.

13. (NEW) The antibody of claim 12, wherein said antibody releases a CEA/NCA-imposed inhibition of differentiation and/or apoptosis in CEA/NCA-producing primary and/or secondary tumor cells.